New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae

References

• Suárez CJ, Lolans K, Villegas MV, et al. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections. Expert Rev Anti Infect Ther. 2005;3(6):915.
   PubMedGoogle Scholar
• Bassetti M, Righi E, Carnelutti A, et al. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16(10):749–761.
   PubMed Web of Science ®Google Scholar
• Farhadi M, Ahanjan M, Goli HR, et al. High frequency of multidrug-resistant (MDR) Klebsiella pneumoniae harboring several β-lactamase and integron genes collected from several hospitals in the north of Iran. Ann Clin Microbiol Antimicrob. 2021;20(1):70.
   PubMed Web of Science ®Google Scholar
• Onorato L, Sarnelli B, D’Agostino F, et al. Epidemiological, clinical and microbiological characteristics of patients with bloodstream infections due to carbapenem-resistant K pneumoniae in Southern Italy: a multicentre study. Antibiotics (Basel). 2022 May 8;11(5):633.
   PubMed Web of Science ®Google Scholar
• Asri NAM, Ahmad S, Mohamud R, et al. Global prevalence of nosocomial multidrug-resistant klebsiella pneumoniae: a systematic review and meta-analysis. Antibiotics (Basel). 2021;10(12):1508.
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Kondratyeva K, Carattoli A, et al. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41(3):252–275.
   PubMed Web of Science ®Google Scholar
• Calbo E, Boix-Palop L, Garau J, et al. Clinical and economic impact of bacterial resistance: an approach to infection control and antimicrobial stewardship solutions. Curr Opin Infect Dis. 2020;33(6):458–463.
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Vena A, et al. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24(5):385–393.
   PubMed Web of Science ®Google Scholar
• Bassetti M, De Waele JJ, Eggimann P, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41(5):776–795.
   PubMed Web of Science ®Google Scholar
• MJ B, RA W. The role of colonization in the pathogenesis of nosocomial infections. Infect Control Hosp Epidemiol. 1996;17(3):193–200.
   PubMed Web of Science ®Google Scholar
• Coello R, Glynn JR, Gaspar C, et al. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect. 1997;37(1):39–46.
   PubMed Web of Science ®Google Scholar
• Olivier CN, Blake RK, Steed LL, et al. Risk of Vancomycin-Resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol. 2008;29(5):404–409.
   PubMed Web of Science ®Google Scholar
• Chang D, Sharma L, Dela Cruz CS, et al. Control Strategies of Klebsiella pneumoniae Infection. Front Microbiol. 2021 Dec 22;12: 750662. DOI:10.3389/fmicb.2021.750662.
   PubMed Web of Science ®Google Scholar
• Martin RM, Bachman MA. Colonization, Infection, and. the Accessory Genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018 Jan 22;8:4. DOI:10.3389/fcimb.2018.00004
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203.
   PubMed Web of Science ®Google Scholar
• Mills JP, Talati NJ, Alby K, et al. The epidemiology of carbapenem-resistant klebsiella pneumoniae colonization and infection among long-term acute care hospital residents. Infect Control Hosp Epidemiol. 2016;37(1):55–60.
   PubMed Web of Science ®Google Scholar
• Borgmann S, Pfeifer Y, Becker L, et al. Findings from an outbreak of carbapenem-resistant Klebsiella pneumoniae emphasize the role of antibiotic treatment for cross transmission. Infection. 2018;46(1):103–112.
   PubMed Web of Science ®Google Scholar
• Cubero M, Cuervo G, Má D, et al. Carbapenem-resistant and carbapenem-susceptible isogenic isolates of Klebsiella pneumoniae ST101 causing infection in a tertiary hospital. BMC Microbiol. 2015;15(1):177.
   PubMedGoogle Scholar
• Zarakolu P, Eser OK, Aladag E, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. Diagn Microbiol Infect Dis. 2016;85(4):466–470.
   PubMed Web of Science ®Google Scholar
• Armand-Lefèvre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57(3):1488–1495.
   PubMed Web of Science ®Google Scholar
• Gharbi M, Moore LS, Gilchrist M, et al. Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit. Int J Antimicrob Agents. 2015;46(2):150–156.
   PubMed Web of Science ®Google Scholar
• Lai C, Chen S-Y, Ko W-C, et al. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 2021 Apr;57(4):106324.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020 Sep 22;9(1):153.
   PubMed Web of Science ®Google Scholar
• Lanzafame, Lanzafame M, Tessari A, et al. Klebsiella pneumoniae resistant to carbapenems: bloodstream infection prevalence before and during the SARS-CoV-2 pandemic in a tertiary level, North-Eastern Italian Hospital. Recenti Prog Med. 2022;113(3):213–215.
   PubMedGoogle Scholar
• Montrucchio G, Corcione S, Sales G, et al. Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: keep an eye on the ball. J Glob Antimicrob Resist. 2020;23:398–400.
   PubMed Web of Science ®Google Scholar
• Hosoda T, Harada S, Okamoto K, et al. COVID-19 and fatal sepsis caused by hypervirulent Klebsiella pneumoniae, Japan, 2020. Emerg Infect Dis. 2021 Feb;27(2):556–559.
   PubMed Web of Science ®Google Scholar
• Borer A, Saidel-Odes L, Eskira S, et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae. Am J Infect Control. 2012 Jun;40(5):421–425. Epub 2011 Sep 9.
   PubMed Web of Science ®Google Scholar
• Schechner V, Kotlovsky T, Kazma M, et al. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected? Clin Microbiol Infect. 2013 May;19(5):451–456.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011 Dec;17(12):1798–1803.
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014;20(12):1357–1362.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Are BM, Pesapane L, et al. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect. 2018 Aug;99(4):413–418. Epub 2018 Apr 3. PMID: 29621600.
   PubMed Web of Science ®Google Scholar
• Liu P, Papadimitrou WZ, Li X, et al. Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection. Chin Med J (Engl). 2018;131(1):56–62.
   PubMed Web of Science ®Google Scholar
• Li X, Luo M, Xu X, et al. Risk factors for carbapenem-resistant klebsiella pneumoniae infection: a meta-analysis. Microb Drug Resist. 2018;24(2):190–198.
   PubMed Web of Science ®Google Scholar
• Cassotta A, Goldstein JD, Durini G, et al. Broadly reactive human CD4 + T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire. Eur J Immunol. 2021;51(3):648–661.
   PubMed Web of Science ®Google Scholar
• Giannella M, Graziano E, Marconi L, et al. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 2017;36(10):1965–1970.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014 Jan;20(1):1–55.
   PubMed Web of Science ®Google Scholar
• Casewell MW, Desai N. Survival of multiply-resistant Klebsiella aerogenes and other Gram-negative bacilli on finger-tips. J Hosp Infect. 1983;4(4):350–360.
   PubMed Web of Science ®Google Scholar
• Casewell M, Phillips I. Hands as route of transmission for Klebsiella species. Br Med J. 1977;2(6098):1315–1317.
   PubMedGoogle Scholar
• http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf. Accessed 15 August 2022
   Google Scholar
• Calderaro A, Buttrini M, Martinelli M, et al. Active surveillance for carbapenemase-producing Klebsiella pneumoniae and correlation with infection in subjects attending an Italian tertiary-care hospital: a 7-year retrospective study. BMJ Open. 2021;11(4):e042290.
   PubMed Web of Science ®Google Scholar
• Zhu J, Li Q, Li X, et al. Successful control of the first carbapenem-resistant Klebsiella pneumoniae outbreak in a Chinese hospital 2017-2019. Antimicrob Resist Infect Control. 2020;9(1):91.
   PubMed Web of Science ®Google Scholar
• Scaglione V, Reale M, Davoli C, et al. Prevalence of antibiotic resistance over time in a third-level University Hospital. Microb Drug Resist. 2022;28(4):425–435.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Mazzaferri F, de Smet AM, et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram- negative bacteria carriers. Clin Microbiol Infect. 2019;25(7):807–817.
   PubMed Web of Science ®Google Scholar
• López-Siles M, Corral-Lugo A, McConnell MJ, et al. Vaccines for multidrug resistant gram negative bacteria: lessons from the past for guiding future success. FEMS Microbiol Rev. 2021;45(3):54.
   Web of Science ®Google Scholar
• Assoni L, Girardello R, Converso TR, et al. Current stage in the development of Klebsiella pneumoniae vaccines. Infect Dis Ther. 2021 Dec;10(4):2157–2175.
   PubMed Web of Science ®Google Scholar
• Lin TL, Yang F-L, Ren C-T, et al. Development of Klebsiella pneumoniae capsule polysaccharide-conjugated vaccine candidates using phage depolymerases. Front Immunol. 2022;13:843183.
   PubMed Web of Science ®Google Scholar
• Marshall JC, Al Naqbi A. Principles of source control in the management of sepsis. Crit Care Nurs Clin North Am. 2011;23(1):99–114. PMID: 21316570.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583–594.
   PubMed Web of Science ®Google Scholar
• Huebner ON, Dittmann K, Henck V, et al. Epidemiology of multidrug resistant bacterial organisms and clostridium difficile in German hospitals in 2014: results from a nationwide one-day point prevalence of 329 German hospitals. BMC Infect Dis. 2016;16(1):467.
   PubMedGoogle Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Nutman A, Lellouche J, Temkin E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26(9):1185–1191.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(9):862–872.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C. Viscoli et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae Infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664–1676.
   PubMed Web of Science ®Google Scholar
• Kumar A, Safdar N, Kethireddy S, et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010;38:1651–1664.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Lewis RE, et al. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11(2):159–177.
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017 Mar 1;64(5):565–571.
   PubMed Web of Science ®Google Scholar
• Perez F, El Chakhtoura NG, Yasmin M, et al. Polymyxins: to combine or not to combine? Antibiotics (Basel). 2019;8(2). DOI:10.3390/antibiotics8020038.
   Web of Science ®Google Scholar
• Petrosillo N, Taglietti F, Granata G. Treatment Options for Colistin Resistant Klebsiella pneumoniae: present and Future. J Clin Med. 2019 Jun 28;8(7):934. PMID: 31261755.
   PubMed Web of Science ®Google Scholar
• Uzairue LI, Rabaan AA, Adewumi FA, et al. Global prevalence of colistin resistance in Klebsiella pneumoniae from bloodstream infection: a systematic review and meta-analysis. Pathogens. 2022;11(10):1092.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of america guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):1109–1116.
   PubMedGoogle Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–547.
   PubMed Web of Science ®Google Scholar
• Pea F, Della Siega P, Cojutti P, et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017;49(2):255–258.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10(1):13–21.
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963–1971.
   PubMed Web of Science ®Google Scholar
• Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1049–1064.
   PubMed Web of Science ®Google Scholar
• De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90.
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(11):e3126.
   PubMed Web of Science ®Google Scholar
• Routsi C, Kokkoris S, Douka E, et al. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45(1):90–93.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240–243.
   PubMed Web of Science ®Google Scholar
• Yu W, Shen P, Bao Z, et al. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2017;50(2):237–241.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):2.
   Web of Science ®Google Scholar
• Lawandi A, Yek C, Kadri SS, et al. IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections. Clin Microbiol Infect. 2022;28(4):465e469.
   Web of Science ®Google Scholar
• Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug- resistant carbapenemase-producing Gram- negative bacteria. Int J Antimicrob Agents. 2014;43(1):52–59.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328.
   PubMed Web of Science ®Google Scholar
• Murri R, Fiori B, Spanu T, et al. Trimethoprim- sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection. 2017;45(2):209–213.
   PubMed Web of Science ®Google Scholar
• Luterbach LC, Boshe A, Henderson HI, et al. The role of trimethoprim/sulfamethoxazole in the treatment of infections caused by open forucarbapenem-resistant Enterobacteriaceaem. Infect Dis. 2019 Jan;6(1):ofy351.
   Google Scholar
• Pachón-Ibáñez ME, Labrador-Herrera G, Cebrero-Cangueiro T, et al. Efficacy of colistin and its combination with rifampin in vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of Klebsiella pneumoniae. Front Microbiol. 2018;9:912.
   PubMed Web of Science ®Google Scholar
• Lagerback P, Khine WWT, Giske CG, et al. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time–kill experiments. J Antimicrob Chemother. 2016;71(8):2321–2325. Epub 2016 Jun 21.
   PubMed Web of Science ®Google Scholar
• Souli M, Karaiskos I, Masgala A, et al. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2017;36(7):1305–1315.
   PubMed Web of Science ®Google Scholar
• Bassetti, Bassetti M, Vena A, et al. Treatment of bloodstream infections due to gram-negative bacteria with difficult-to-treat resistance. Antibiotics. 2020;9(9):632.
   Web of Science ®Google Scholar
• Shields R, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17.
   PubMed Web of Science ®Google Scholar
• Van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Castón JJ, Cano A, Pérez-Camacho I, et al. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother. 2022;77(5):1452–1460.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. J Antimicrob Chemother. 2021 Feb 11;76(3):775–783.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544.
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878.
   PubMed Web of Science ®Google Scholar
• Di Bella S, Giacobbe DR, Maraolo AE, et al. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. J Glob Antimicrob Resist. 2021;25:268–281. Epub 2021 Apr 23.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane–tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014;74(1):31–51.
   PubMed Web of Science ®Google Scholar
• Sharp M, Dohme. ZERBAXA (ceftolozane and tazobactam) for injection full prescribing information. Whitehouse Station (NJ): Merck; 2015.
   Google Scholar
• Carvalhaes CG, Castanheira M, Sader HS, et al. Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. Diagn Microbiol Infect Dis. 2019;94(1):93–102.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299–1311.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Giacobbe DR, et al. Ceftolozane/tazobactam for treatment of severe esbl-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study). Open Forum Infect Dis. 2020;7(5):ofaa139.
   PubMed Web of Science ®Google Scholar
• Kuo S-C, Liu C-E, Lu P-L, et al. Activity of ceftolozane-tazobactam against gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016. Int J Antimicrob Agents. 2020;55(3):105883.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Lomovskaya O, Dudley MN, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62:1.
   Web of Science ®Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):12.
   Web of Science ®Google Scholar
• Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2018;37(8):1411–1419.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Cascio A, et al. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC Antimicrob Resist. 2022;4(1):dlac022.
   PubMedGoogle Scholar
• Real-world AS, Lagnf AM, Morrisette T. Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis. 2021;8(8):ofab371.
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59(8):5029–5031.
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808.
   PubMed Web of Science ®Google Scholar
• Titov I, Wunderink RG, Roquilly A, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021;73(11):e4539–e4548.
   PubMed Web of Science ®Google Scholar
• de Sousa Coelho F, Mainardi JL. The multiple benefits of second-generation beta-lactamase inhibitors in treatment of multidrug-resistant bacteria. Infect Dis Now. 2021;S2666-9919(20):00017–2.
   Google Scholar
• Vazquez-Ucha JC, Arca-Suarez J, Bou G. Beceiro new carbapenemase inhibitors: clearing the way for the beta-lactams. Int J Mol Sci. 2020;21(23):9308.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis. 2020 May 14;7. PMID: 32489663; PMCID: PMC7238785. DOI:10.1177/2049936120912049.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021Feb; 21(2):213–225. Epub 2020 Oct 12
   PubMed Web of Science ®Google Scholar
• Naseer S, Weinstein EA, Rubin DB, et al. US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja®). Clin Infect Dis. 2021 Jun 15;72(12):e1103–e1111.
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66(5):e0214221.
   PubMed Web of Science ®Google Scholar
• Clark AJ, Burgess DS. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance. Ther Adv Infect Dis. 2020;7:2049936120952604.
   Web of Science ®Google Scholar
• McKinnell JA, Dwyer JP, Talbot GH. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med. 2019;380(8):791–793.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M. In vitro activity of eravacycline against carbapenem-resistant enterobacteriaceae and acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(6):3840–3844.
   PubMed Web of Science ®Google Scholar
• Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2113–2118;58. DOI:10.1128/AAC.02036-13.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23(11):1575–1584.
   PubMed Web of Science ®Google Scholar
• Abrahamian FM, Sakoulas G, Tzanis E, et al. Omadacycline for acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;69(1):S23–s32.
   PubMedGoogle Scholar
• Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–527.
   PubMed Web of Science ®Google Scholar
• Xiao M, Huang -J-J, Zhang G, et al. Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. BMC Microbiol. 2020 Nov 16;20(1):350.
   PubMed Web of Science ®Google Scholar
• Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary gram-negative pathogens from New York City Hospitals. Microb Drug Resist. 2021Feb; 27(2):190–195. Epub 2020 Jun 22
   PubMed Web of Science ®Google Scholar
• Chahine EB. Ceftaroline: potential role and implications in an era of escalating antimicrobial resistance. Am J Health Syst Pharm. 2011;68(6):489.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. SPC of ceftaroline fosamil (Zinforo™). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002252/WC500132586.pdf, Accessed 28 July 2022.
   Google Scholar
• Ghamrawi RJ, Neuner E, Rehm SJ, et al. Ceftaroline fosamil: a super-cephalosporin? Cleve Clin J Med. 2015;82(7):437–444.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Farrell DJ, et al. Activity of ceftaroline-avibactam tested against gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012Sep; 56(9):4779–4785. Epub 2012 Jun 25
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Garello P, Vickers A, et al. Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. J Antimicrob Chemother. 2021 May 12;76(6):1511–1522.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT04979806.
   Google Scholar
• Mushtaq S, Vickers A, Woodford N, et al. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2019;74(4):953–960.
   PubMed Web of Science ®Google Scholar
• Hagihara M, Kato H, Sugano T, et al. In vivo pharmacodynamics of β-lactams/nacubactam against carbapenem-resistant and/or carbapenemase-producing enterobacter cloacae and Klebsiella pneumoniae in murine pneumonia model. Antibiotics. 2021;10(10):1179.
   Google Scholar
• Shabir S, Inglis D, Manzoor S, et al. P362 development of the first UK licenced faecal microbiota transplant service: results of first year’s activity. Gut. 2021;70(228):A228.
   PubMedGoogle Scholar
• Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):29.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K pneumoniae. Clin Microbiol Infect. 2016;22(5): 444–450
   PubMed Web of Science ®Google Scholar
• Russo A, Falcone M, Gutiérrez-Gutiérrez B, et al. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018;52(5):577–585.
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138.
   PubMed Web of Science ®Google Scholar
• Russo A, Giuliano S, Ceccarelli G, et al. Comparison of septic shock due to multidrug-resistant acinetobacter baumannii or klebsiella pneumoniae carbapenemase-producing K pneumoniae in intensive care unit patients. Antimicrob Agents Chemother. 2018;62:6.
   Web of Science ®Google Scholar
• Russo A, Marincola Cattaneo F, Brunetti G, et al. Clinical features and outcome of difficult-to-treat infections in a high-intensity medical care ward. Minerva Med. 2020. DOI:10.23736/S0026-4806.20.06467-8
   PubMedGoogle Scholar
• Bassetti M, Russo A, Carnelutti A, et al. Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opin Drug Saf. 2018;17(7):669–680.
   PubMed Web of Science ®Google Scholar
• Russo A, Gavaruzzi F, Ceccarelli G, et al. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection. 2022;50(1):83–92.
   PubMed Web of Science ®Google Scholar
• Russo A, Berruti M, Giacobbe DR, et al. Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. Expert Rev Anti Infect Ther. 2021 Aug;19(8):983–991.
   PubMed Web of Science ®Google Scholar
• Russo A. Spotlight on new antibiotics for the treatment of pneumonia. Clin Med Insights Circ Respir Pulm Med. 2020 Dec 20;14: 1179548420982786. DOI:10.1177/1179548420982786.
   Web of Science ®Google Scholar
• Russo A, Bassetti M, Bellelli V, et al. *Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant acinetobacter baumannii: a prospective, observational study. Infect Dis Ther. 2021 Mar;10(1):187–200. Epub 2020 Oct 17. PMID: 33068255; PMCID: PMC7568458.
   PubMed Web of Science ®Google Scholar